AZ Plans To Triple Spending On Russia Drugs Over Next Five Years
This article was originally published in PharmAsia News
AstraZeneca said it plans to at least triple its current investment in Russia, to as much as $1.2 billion by 2017 to develop new products in targeted drugs, biomarkers, predictive medicine and design of clinical studies.
You may also be interested in...
With a pipeline of over 35 ANDAs, India's Caplin Steriles plans to launch five generic injectables through a strategic partnership with Xellia Pharma in the US market. Out of the five ANDAs, one has been approved and is ready for launch.
Sanofi has received formal approval from the European Commission for its insulin aspart biosimilar.
Europe's self-care industry urges the European Commission to use Rx-to-OTC switch and real world evidence to widen access to OTC medicines in the region as part of its new pharmaceutical strategy.